SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis

Launched by EMORY UNIVERSITY · Sep 21, 2020

Keywords

ClinConnect Summary

The SAFE Study is a clinical trial that is looking at the safety of a treatment called aPCC for patients with Hemophilia A who are already using another medication called emicizumab. This study is important for both children and adults who experience bleeding problems, especially when they have developed inhibitors that make it harder for their bodies to control bleeding. The goal is to see how well a personalized dose of aPCC works during bleeding episodes or before medical procedures.

To be eligible for this trial, participants should be at least 6 years old and have moderately severe Hemophilia A, which means they have very low levels of a specific blood factor needed for clotting. They also need to have documented high levels of inhibitors in their blood. Participants will be monitored closely during the study to ensure their safety and to gather important information on how effective the treatment is. The study also aims to include people who are planning to undergo minor or major medical procedures in the next two years, as this data is crucial for understanding the treatment's effectiveness in real-life situations.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Moderately severe hemophilia A, defined as FVIII level \<0.05 IU/mL before development of an inhibitor
• • Age ≥6 years of age at time of informed consent
• • Documented on 2 occasions a high titer inhibitor (\>5 BU/mL) with a 72-hour washout within 2 years of enrollment
• • Parent/guardian (Legally Authorized Representative) or the patient has provided written informed consent
• • Adequate hematologic function (Hgb \>8 g/dL and platelet count \>100,000 µL)
• • Adequate hepatic function (total bilirubin ≤1.5 x ULN and both AST/ALT ≤3x ULN at screening (excluding known Gilbert's)
• • Adequate renal function (≤2.5 x ULN and CrCl ≥30 mL/min)
• Exclusion Criteria:
• • Inherited or acquired bleeding disorder other than hemophilia A excluding low VWF (\>30% VWF:RCo or VWF:GP1bm)
• • Had an active bleed requiring factor therapy at screening
• • Previous or current treatment for thromboembolic disease or signs of thromboembolic disease (excluding previously resolved line-associated thrombosis)
• • Had a surgical procedure 14 days before screening
• • Conditions that may increase the risk of bleeding or thrombosis
• • If the patient is treated with rFVIIa or aPCC seven days before screening
• • History of clinically significant hypersensitivity associated with monoclonal antibody therapies or components of the emicizumab injection
• • Had current use of any medication other than emicizumab that could affect the coagulation system.
• • Known HIV infection with CD4 count \<200 cells/µL within 24 weeks before screening. Testing is not required if \<35 years of age.
• • Use of systemic immunomodulators at enrollment or planned use during the study
• • Participants who are at high risk for TMA (for example, have a previous medical/family history of TMA), in the investigator's judgment
• • Concurrent disease, treatment, or abnormality in clinical laboratory tests that could interfere with the conduct of the study, may pose an additional risk, or would, in the opinion of the investigator, preclude the participant's safe participation in and completion of the study